Brucellosis medical therapy

Revision as of 20:13, 5 February 2016 by Danitza Lukac (talk | contribs)
Jump to navigation Jump to search

Brucellosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Brucellosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Principles of diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT Scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Brucellosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Brucellosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Brucellosis medical therapy

CDC on Brucellosis medical therapy

Brucellosis medical therapy in the news

Blogs on Brucellosis medical therapy

Directions to Hospitals Treating Brucellosis

Risk calculators and risk factors for Brucellosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Danitza Lukac

Overview

The mainstay of therapy for brucellosis is antimicrobial therapy. The preferred regimen for uncomplicated brucellosis is a combination of Doxycycline and Streptomycin. Rifampin is the drug of choice for brucellosis in pregnancy. For children less than 8 years of age, the preferred regimen is either Gentamycin or a combination of Trimethoprim-sulfamethoxazole and Streptomycin.[1][2]

Medical Therapy

Antimicrobial Regimen

  • 1.Uncomplicated brucellosis in adults and children ≥8yrs of age
  • 2. Complications of brucellosis
  • 2.1 Spondylitis
  • 2.2 Neurobrucellosis
  • 2.3 Brucella endocarditis
  • 3. Pregnancy
  • 4.For children < 8 yrs of age
  • 5.Post-exposure prophylaxis
  • Preferred regimen (1): Doxycycline 100mg PO bid for at least 3 weeks
  • Preferred regimen (2): TMP/SMZ 160 mg/800mg PO bid for at least 3 weeks
  • Prophylaxis for exposure to Brucella species routinely consists of a combination of doxycycline and rifampicin. RB51, however, is resistant to rifampin in vitro, so rifampin is not recommended.
  • Both those with high and low risk exposures should be monitored for the development of symptoms of brucellosis. Routine serologic tests for brucellosis will not be effective in monitoring for infection. Monitoring, from the last exposure, should include:
    • For 4 weeks: temperature should be actively monitored
    • For 6 months: broader symptoms of brucellosis should be passively monitored.

Reference

  1. 1.0 1.1 Brucellosis. Wikipedia. https://en.wikipedia.org/wiki/Brucellosis. Accessed on February 1, 2016
  2. Brucellosis. CDC. http://www.cdc.gov/brucellosis/treatment/index.html. Accessed on February 5, 2016
  3. Brucellosis. Wikipedia. https://en.wikipedia.org/wiki/Brucellosis. Accessed on February 1, 2016
  4. Corbel, Michael (2006). Brucellosis in humans and animals. Geneva: World Health Organization. ISBN 9241547138.
  5. Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
  6. Brucellosis. CDC. http://www.cdc.gov/brucellosis/veterinarians/rb51-reduce-risk.html. Accessed on February 5, 2016

Template:WH Template:WS